Breaking News, Collaborations & Alliances

Pharmacyclics, Roche Enter Clinical Supply Pact

Will study IMBRUVICA and GAZYVA in CLL/SLL/NHL

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pharmacyclics, Inc. has entered into a master clinical drug supply agreement with Roche to evaluate the safety, tolerability and efficacy of IMBRUVICA (ibrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor, in combination with GAZYVA (obinutuzumab), a new CD20-directed antibody in patients with non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).    Pharmacyclics will initially conduct a Phase III study in CLL/SLL, and plans to evaluate t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters